Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Pasquali, Sandro [VerfasserIn]   i
 Kasper, Bernd [VerfasserIn]   i
Titel:The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma
Titelzusatz:revisiting the results of the EORTC-STBSG 62931 randomised trial
Verf.angabe:Sandro Pasquali, Sara Pizzamiglio, Nathan Touati, Saskia Litiere, Sandrine Marreaud, Bernd Kasper, Hans Gelderblom, Silvia Stacchiotti, Ian Judson, Angelo P. Dei Tos, Paolo Verderio, Paolo G. Casali, Penella J. Woll, Alessandro Gronchi on behalf of the EORTC-Soft Tissue and Bone Sarcoma Group
E-Jahr:2019
Jahr:25 January 2019
Umfang:10 S.
Fussnoten:Gesehen am 10.09.2019
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2019
Band/Heft Quelle:109(2019), Seite 51-60
ISSN Quelle:1879-0852
Abstract:Background - This study was aimed at determining whether patients with high-risk soft tissue sarcoma (STS), as identified using the nomogram Sarculator, benefitted from adjuvant chemotherapy in the EORTC-STBSG 62931 randomised controlled trial (RCT), which failed to detect an impact for adjuvant doxorubicin plus ifosfamide (Adj) over observation (Obs). - Methods - Patients with extremity and trunk wall STS in the EORTC-STBSG 62931 RCT were analysed (N = 290/351). Ten-year predicted probability of overall survival (pr-OS) was calculated using the prognostic nomogram Sarculator. Patients were grouped into three categories of predicted pr-OS: high (pr-OS>66%), intermediate (51<pr-OS≤66) and low (pr-OS≤51%). OS and disease-free survival (DFS) were calculated. - Results - Nomogram pr-OS was dispersed (median 72%, interquartile range 57-83%) and had prognostic value for OS and DFS (log-rank test: P < 0.001). One hundred seventy, 68 and 52 patients had high (58.6%, 90 Obs/80 Adj), intermediate (23.5%, 34 Obs/34 Adj) and low pr-OS (17.9%, 24 Obs/28 Adj), respectively. Adjuvant chemotherapy halved the risk of recurrence (hazard ratio [HR] = 0.46, 95% confidence interval [CI] 0.24-0.89) and death (HR = 0.46, 95% CI 0.23-0.94) in the low pr-OS category, while no effect was detected in intermediate and high pr-OS categories. To strengthen these findings, study participants with pr-OS<60% were combined (N = 80, 27.6%, 39 Obs/41 Adj), and a significant DFS (HR = 0.49, 95% CI 0.28-0.85) and OS (HR = 0.50, 95% CI 0.30-0.90) benefit was detected. - Conclusion - Patients of the EORTC-STBSG 62931 RCT with extremity and trunk wall STS and a low predicted pr-OS (high-risk patients) had better outcomes when treated with adjuvant chemotherapy. This may help reconcile the disparate results of clinical studies on adjuvant/neoadjuvant chemotherapy in STS.
DOI:doi:10.1016/j.ejca.2018.12.009
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2018.12.009
 Volltext: http://www.sciencedirect.com/science/article/pii/S0959804918315557
 DOI: https://doi.org/10.1016/j.ejca.2018.12.009
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adjuvant
 Chemotherapy
 High risk
 Overall survival
 Randomised controlled trial
 Soft tissue sarcoma
K10plus-PPN:1675736227
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68426218   QR-Code
zum Seitenanfang